Vox Sanguinis International Forum on application of fetal blood grouping

Fetal RHD genotyping is provided for alloimmunised women [3, 4]. With regard to the situation for all RhD negative pregnant women: The R & D division of the Blood Service is currently carrying out an economic analysis of RHD genotyping to target pregnant women for antenatal and post-partum anti-D prophylaxis. This follows a feasibility study into the uptake and acceptance of the maternal blood test in two obstetric populations. Any decision to introduce fetal blood grouping to a broader population group than alloimmunised women will be dependent on the outcomes of R&D projects currently underway and further business analysis. The Blood Service will then consult with external and government stakeholders whether to introduce the service to alloimmunisedwomen or all RhD-negative pregnant women. A separate R & D study is reviewing the application of a droplet digital PCR (ddPCR) assay for non-invasive detection of fetal KEL*01.01 in isoimmunised pregnancies.

[1]  B. Veldhuisen,et al.  Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands , 2016, British Medical Journal.

[2]  A. Bräuninger,et al.  Non-invasive fetal platelet and red cell blood group genotyping with the use of targeted massively parallel sequencing of maternal plasma cell-free DNA , 2016 .

[3]  M. Dziegiel,et al.  Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. , 2015, Cold Spring Harbor perspectives in medicine.

[4]  M. Westgren,et al.  Targeted Routine Antenatal Anti-D Prophylaxis in the Prevention of RhD Immunisation - Outcome of a New Antenatal Screening and Prevention Program , 2013, PLoS ONE.

[5]  F. Wagner,et al.  Evaluation of single‐nucleotide polymorphisms as internal controls in prenatal diagnosis of fetal blood groups , 2013, Transfusion.

[6]  M. Westgren,et al.  Noninvasive Single-Exon Fetal RHD Determination in a Routine Screening Program in Early Pregnancy , 2012, Obstetrics and gynecology.

[7]  P. Scheffer,et al.  Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7‐year clinical experience , 2011, BJOG : an international journal of obstetrics and gynaecology.

[8]  J. Pellegrino,et al.  Fetal RHD genotyping by analysis of maternal plasma in a mixed population , 2011, Journal of clinical laboratory analysis.

[9]  K. Gutensohn,et al.  The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible , 2008, Transfusion.

[10]  Chunming Ding,et al.  Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. , 2006, Clinical chemistry.

[11]  N. Avent,et al.  Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service , 2002, Transfusion.